Harish Chowdary Gorrepati/LinkedIn
Sep 1, 2026, 15:09
Harish Chowdary Gorrepati: The HALT Paradox After TAV
Harish Chowdary Gorrepati, Interventional Cardiologist at Sri Venkateswara Institute of Medical Sciences (SVIMS), Tirupati, Fellow at Heart Center UMC, shared a post on LinkedIn:
“NOTION-4 Trial | TAVR and Antithrombotic Therapy.
Short-term DOAC after TAVR significantly reduced HALT at 3 months (31.8 percent – 12.1 percent), but this benefit was not sustained at 12 months (32.2 percent versus 28.3 percent; P=0.54).
Importantly, bleeding/clinical events were numerically higher with the DOAC strategy.
Key message: Reducing leaflet thrombosis on CT does not necessarily translate into better clinical outcomes.
SAPT remains the preferred strategy for patients without another indication for oral anticoagulation.”
Stay updated with Hemostasis Today.
-
Oct 20, 2026, 01:43Oliver Weingärtner: Deprescribing of Lipid Lowering Drug after MI is Associated with Cardiovascular Events
-
Oct 19, 2026, 19:44Where You Live Should not Determine Whether You Receive Care – World Federation of Hemophilia
-
Oct 19, 2026, 19:42Belen Bianco: Prevention, Early Suspicion and an Interdisciplinary Approach Save Lives
-
Oct 19, 2026, 19:40Christina Chrysohoou: Catheter-Based LAAC vs OAC for Stroke Prevention in Atrial Fibrillation
-
Oct 19, 2026, 19:38Matthew Flick: A Two-Day Research Meeting on Fibrinogen, Hemostasis and Thrombosis
-
Oct 19, 2026, 19:37Hayat Saeed: Excited to Share Our Publication on the FGL1–Hepcidin Axis in Iron Homeostasis and Disease
-
Oct 19, 2026, 19:08IPAW 2026 Comes to a Close, but the Work Continues – PPTA
-
Oct 19, 2026, 17:44Paul Riley: Moderating a Webinar on Anticoagulation Monitoring
-
Oct 19, 2026, 16:36Christopher Pittman: Blood Clot Prevention Cannot End at Hospital Discharge